FDA Grants Accelerated Approval to Genentech’s Venclexta® for Acute Myeloid Leukemia

November 22, 2018 Scipreneur Private Limited 0

FDA Grants Accelerated Approval to Genentech’s Venclexta® for Acute Myeloid Leukemia By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Venclexta® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or [..]